戻る Agenda
[V1-S4] The Changing Environment in the World and the Impact on the Pharmaceutical Industry
Session Chair(s)
Kihito Takahashi
Head of R&D/Medical Affairs Hub Japan
Swedish Orphan Biovitrium (SOBI) Japan, Japan
There was a worldwide impact event such as Brexit in EU and presidential election in US last year. This session is made up of 2 parts, the first part is Brexit. We would like to discuss the influence of Brexit for pharmaceutical companies in the world. On the other hand,” the international Summit of Heads of Medicines Regulatory Agencies” and” meeting of the International Coalition of Medicines Regulatory Authorities (ICMRA)” will convene for the first time in Japan, at the Kyoto in October and the representatives from a variety of countries and industries will discuss innovative technological developments and their practical applications, both current status and future expectations. In this session, we would like to confirm the movement in the world and discuss about the impacts and prospect in Japan.
Speaker(s)
The Brexit and the Possible Implications for Marketing Authorisation Holders
Peter Bachmann
Federal Institute for Drugs and Medical Devices (BfArM), Germany
Deputy-Head, European Union and International Affairs
The Changing Environment in the World and the Impact on the Pharmaceutical Industry
Kazuhiko Mori, PhD, MSc
Japan Pharmaceutical Manufacturers Association (JPMA), Japan
Senior Managing Director
Alberto Grignolo, PhD
DIA Global Forum, United States
Editor-in-Chief
Takuko Sawada
Shionogi & Co., Ltd., Japan
Director and Vice Chairperson of the Board
Tadaaki Taniguchi, MD, PhD
AstraZeneca K.K., Japan
Executive Director and Strategic Officer, China Development, Emerging Market R&D